VERU INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
VERU INC. (VERU) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $200 for the 9-month period ending 2024-06-30, per its 10-Q filed 2024-08-08.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2024-12-16
- VERU INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-09-30 was $14.00K.
- VERU INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2014-09-30 was $65.00K.
- VERU INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2013-09-30 was $0.00, a 100.00% decline year-over-year.
- VERU INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2012-09-30 was $6.38M.
- VERU INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $500.00K, a 93.83% decline from fiscal 2022.
- VERU INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $8.10M, a 11.96% decline from fiscal 2021.
- VERU INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $9.20M, a 736.36% increase from fiscal 2020.
- VERU INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $1.10M, a 301.46% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2024-06-30 | $200.00 10-Q · filed 2024-08-08 | |||
| 2023-09-30 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-16 | $500.00K 10-K · filed 2024-12-16 | ||
| 2023-06-30 | $486.00K 10-Q · filed 2024-08-08 | |||
| 2022-09-30 | $8.10M 10-K/A · filed 2024-04-01 | |||
| 2021-09-30 | $9.20M 10-K · filed 2022-12-05 | |||
| 2020-09-30 | $1.10M 10-K · filed 2021-12-02 | |||
| 2019-09-30 | $274.00K 10-K · filed 2020-12-10 | |||
| 2018-09-30 | $44.00K 10-K · filed 2019-12-12 | |||
| 2016-09-30 | $0.00 10-K · filed 2016-12-12 | |||
| 2015-09-30 | $0.00 10-K · filed 2016-12-12 | |||
| 2014-09-30 | $65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-12 | $154.00K 10-K · filed 2016-12-12 | ||
| 2014-06-30 | $89.00K 10-Q · filed 2015-07-30 | |||
| 2013-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-02 | $272.00K 10-K · filed 2015-12-02 | ||
| 2013-06-30 | $272.00K 10-Q · filed 2013-08-01 | |||
| 2012-09-30 | $6.38M derived: 10-K 12 month − 10-Q 9 month · filed 2014-12-02 | $6.38M derived: sum of 2 quarters · filed 2014-12-02 | $6.38M derived: sum of 3 quarters · filed 2014-12-02 | $6.89M 10-K · filed 2014-12-02 |
| 2012-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-08-01 | $0.00 derived: sum of 2 quarters · filed 2013-08-01 | $510.00K 10-Q · filed 2013-08-01 | |
| 2012-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-05-02 | $510.00K 10-Q · filed 2013-05-02 | ||
| 2011-12-31 | $510.00K 10-Q · filed 2013-01-30 | |||
| 2010-09-30 | $1.79M 10-K · filed 2012-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |